Do calcium carbonate (Calprolate) and flecainide interact, and how should their dosing be timed to avoid interaction?

Calcium Carbonate and Flecainide: No Clinically Significant Interaction

There is no documented interaction between calcium carbonate (Calprolate) and flecainide, and no special dosing timing is required. The FDA labeling for flecainide does not list calcium carbonate as an interacting drug, and no evidence exists demonstrating any pharmacokinetic or pharmacodynamic interaction between these medications 1.

Key Evidence

FDA Drug Label Findings

The comprehensive FDA drug interaction section for flecainide explicitly lists all known drug interactions, including:

• Digoxin (13-19% increase in levels)
• Propranolol (20% increase in flecainide levels)
• Amiodarone (can double flecainide levels)
• Cimetidine (30% increase in flecainide levels)
• Verapamil and disopyramide (contraindicated due to negative inotropic effects)
• CYP2D6 inhibitors like quinidine

Calcium carbonate is notably absent from this list 1.

Protein Binding Considerations

Flecainide is not extensively bound to plasma proteins, and the FDA label specifically states: "Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants) would not be expected" 1. Calcium carbonate does not affect protein binding or the cytochrome P450 system relevant to flecainide metabolism.

Guideline Support

The 2015 ACC/AHA/HRS guidelines for supraventricular tachycardia management list specific drug interactions with flecainide (amiodarone, digoxin, ritonavir, saquinavir, tipranavir) but do not mention calcium-containing compounds 2.

Clinical Implications

• No dose adjustment needed: Administer both medications at their standard therapeutic doses
• No timing separation required: Unlike calcium's interaction with fluoroquinolones (which requires 2-hour separation 3), no such timing consideration exists for flecainide
• Monitor standard flecainide parameters: Continue routine monitoring of QRS duration, PR interval, and cardiac function as indicated for flecainide therapy regardless of calcium supplementation 1

Important Flecainide Monitoring (Unrelated to Calcium)

When prescribing flecainide, focus on the actual contraindications and monitoring needs:

• Avoid in structural heart disease, particularly obstructive coronary disease 4
• Monitor for QRS widening (should not exceed 25% from baseline)
• Watch for negative inotropic effects, especially when combined with beta-blockers or calcium channel blockers 5, 6
• Reduce dose by 50% if adding amiodarone 2